ArticleOncotarget2017
The ovarian cancer oncobiome.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06272240 (Study of the Role of the Tumor Microenvironment in Ovarian Cancer), which is not on this map. Cited by 132 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Role of the Tumor Microenvironment in Ovarian Cancer
Who cites it
132 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Guideline for designing microbiome studies in neoplastic diseases.GeroScience · 2024Guideline
- The Application of High-Throughput Technologies for the Study of Microbiome and Cancer.Frontiers in genetics · 2021Pooled it
- Oncobiome relation with HPV and Gynecological cancer.Molecular biology reports · 2026Review
- Review
- Review
- Review
- Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential.Genes & diseases · 2026Review
- Vaginal Microbiota and Ovarian Cancer: A New Frontier in Immunomodulation and Diagnosis.Immunology · 2026Review
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Bacterial Infections Role in Gynecological Cancers Development: Narrative Review.Cancer reports (Hoboken, N.J.) · 2026Review
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- The role of the microbiome in gynecological cancers: implications for diagnosis and treatment.Frontiers in immunology · 2026Review
- Distinguishing the significance of blood microbes in epithelial ovarian cancer.Gut microbes reports · 2026Article
- The specific hallmarks, emerging roles, key mechanisms, and clinical applications of intra-tumoral microbiota in human cancers.Genes & diseases · 2026Review
- HPV profiles in Botswana: An analysis of healthy women, cervical intraepithelial neoplasia, and invasive cervical cancer.Gynecologic oncology reports · 2025Article
- Tumor-resident microbiota in gynecologic malignancies: Molecular mechanisms, clinical correlations, and translational potential.iScience · 2025Review
- The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies.Cells · 2025Review
- Microbial regulators of physiological and reproductive health in women of reproductive age: their local, proximal and distal regulatory roles.NPJ biofilms and microbiomes · 2025Review
- Disrupted Cervicovaginal Microbiota: Its Role inInternational journal of molecular sciences · 2025Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Humans and other mammals are colonized by microbial agents across the kingdom which can represent a unique microbiome pattern. Dysbiosis of the microbiome has been associated with pathology including cancer. We have identified a microbiome signature unique to ovarian cancers, one of the most lethal malignancies of the female reproductive system, primarily because of its asymptomatic nature during the early stages in development. We screened ovarian cancer samples along with matched, and non-matched control samples using our pan-pathogen array (PathoChip), combined with capture-next generation sequencing. The results show a distinct group of viral, bacterial, fungal and parasitic signatures of high significance in ovarian cases. Further analysis shows specific viral integration sites within the host genome of tumor samples, which may contribute to the carcinogenic process. The ovarian cancer microbiome signature provides insights for the development of targeted therapeutics against ovarian cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.